Navigation Links
Jennerex Appoints Lara Longpre to Chief Operating Officer

SAN FRANCISCO, Aug. 25 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced the appointment of Lara Longpre to the position of chief operating officer. Ms. Longpre will be responsible for the development of the company's lead product, JX-594, as well as Jennerex's other product candidates in development and will lead the clinical operations and research, manufacturing, regulatory and quality functions. Ms. Longpre has served as a consultant to Jennerex since 2009.

"Lara's extensive experience in developing therapeutics will make her a key member of our executive management team," said David H. Kirn, M.D., president and chief executive officer of Jennerex. "Her systematic and meticulous approach to operations, combined with her demonstrated leadership ability, make Lara the ideal person to direct the development of JX-594 as we move toward late stage clinical trials in advanced liver cancer."

Ms. Longpre brings to Jennerex over 17 years of broad clinical research, operations, and leadership expertise in all stages of clinical development.  Prior to Jennerex, Ms. Longpre held the position of  senior vice president, clinical and corporate affairs at MedGenesis Therapeutix and held senior positions at PRA International, a global CRO, including vice president of proposals and contracts, vice president of quality and process management, director of global regulatory affairs, and director of operations. She has directly managed several pivotal Phase 3 trials, and has specific expertise in project management, clinical operations, and quality management systems, including achieving ISO 9001:2000 registration and ensuring Sarbanes-Oxley compliance while at an international CRO. Ms. Longpre holds an M.Sc. in Medical Science from Harvard Medical School, an MBA from Queens University, and B.A. from Cornell University.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib.  Prior, published studies designed to establish dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types.  JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the reduction of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against cancer cells.  Jennerex is headquartered in San Francisco and has research and development operations in Ottawa, Canada and Pusan, South Korea.  For more information about Jennerex, please visit

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. West Pharmaceutical Services, Inc. Appoints New Director
Post Your Comments:
(Date:11/26/2015)... the Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... the Netherlands has found that immunotherapy can ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Wound Care Market by Type (Dressings, Therapy Devices, Active ... Facility, Out-Patient Facility), and Geography - Global Forecast to ... --> --> The purpose of ... forecast of the global advanced wound care market. It ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a ... customers 10% off of their purchase of lice treatment product. In addition, customers will ... to a company spokesperson. “Finding lice is a sure way to ruin the holidays, ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ProSidebar: ... in Final Cut Pro X. With ProSidebar: Fasion, video editors can easily add ... ProSidebar as a minimalist title opener. Utilize presets featuring self-animating drop zones, lines, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the Radiology ... Building Better Radiology Marketing Programs meeting will showcase some of the best ... at Caesars Palace in Las Vegas with a pre-conference session on a collaborative ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
Breaking Medicine News(10 mins):